34403-39-9

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-pyridinylmethyl)-1H-Isoindole-1,3(2H)-dione is used as a PDE10A inhibitor for its potential therapeutic applications in the treatment of neurological and psychiatric disorders, such as schizophrenia and Huntington's disease. Its ability to modulate the levels of intracellular signaling molecules like cAMP and cGMP makes it a promising candidate for these conditions.
Used in Neurological Disorders Treatment:
2-(4-pyridinylmethyl)-1H-Isoindole-1,3(2H)-dione is used as a therapeutic agent for the treatment of neurological disorders, specifically targeting the PDE10A enzyme. Its inhibition of this enzyme can help regulate the levels of cAMP and cGMP, which are crucial for various cellular processes and may contribute to the alleviation of symptoms associated with neurological disorders.
Used in Psychiatric Disorders Treatment:
2-(4-pyridinylmethyl)-1H-Isoindole-1,3(2H)-dione is used as a therapeutic agent for the treatment of psychiatric disorders, such as schizophrenia. Its ability to selectively inhibit the PDE10A enzyme can help in modulating the levels of intracellular signaling molecules, potentially leading to improvements in the symptoms of psychiatric disorders.

Upstream product

• 3731-53-1 4-(aminomethyl)pyridine 
• 85-44-9 phthalic anhydride 

Downstream Products

• 1191083-53-0 [Au(PPh₃)(4-aminomethyl-N-phthalimidopyridine)](OTf) 
• 3731-53-1 4-(aminomethyl)pyridine 

Relevant academic research and scientific papers

Alkoxide-Catalyzed Hydrosilylation of Cyclic Imides to Isoquinolines via Tandem Reduction and Rearrangement

An alkoxide-catalyzed hydrosilylation of cyclic imides to isoquinolines was realized via tandem reduction and rearrangement. Using TMSOK as the catalyst and (EtO)2MeSiH as the reductant, a series of cyclic imides containing different functional groups were reduced to the corresponding 3-aryl isoquinolines in moderate to good yields. The scenario of the reaction pathway was supposed to involve the reduction of imides to ω-hydroxylactams, which underwent rearrangement in the presence of a base catalyst, and then the carbonyl reduction, followed by siloxy elimination.

Phthalimide-N-sulfonic acid, an efficient catalyst for the synthesis of various isoindoline-1,3-dione derivatives

An environmentally friendly method is described for the synthesis of various isoindoline-1,3-dione derivatives from the reaction of phthalic anhydride with aromatic/aliphatic amines in ethanol at 80 °C by phthalimide-N-sulfonic acid as an efficient heterogeneous acid catalyst. Some advantages include the metal-free and environmentally friendly protocol, simple operation and reusable processes, easy recovery, short reaction times, and high yields.

New anti-inflammatory N-pyridinyl(alkyl)phthalimides acting as tumour necrosis factor-α production inhibitors

This paper describes the synthesis of N-pyridinyl(alkyl)phthalimides related to N-phenyl-4,5,6,7-tetrafluorophthalimides known to be inhibitors of tumour necrosis factor-α (TNFα) production. Pharmacomodulation at the phthalimidic nitrogen led to the selection of two pharmacophoric fragments (2,4-lutidinyl and β-picolyl), allowing significant inhibition of TNFα production (compounds 12 and 17). Variation of the substituents linked to the homocycle of their phthalimide scaffold indicated that high (TNFα production) inhibitory potency could be achieved, notably by 5-fluoro, 4- or 5-nitro, 5-amino and especially tetrafluoro substitution. The most active compound, N-(pyridin-3-ylmethyl)-4,5,6,7-tetrafluorophthalimide (32) (84% inhibition at 10 μM), also produced an anti-oedematous effect in the PMA-induced mouse-ear swelling test. Although less active than dexamethasone, it exerted a marked reduction in ear thickness after oral administration (63% vs. 85% for dexamethasone at 0.2 mM kg-1) and remained efficient after topical application (46% vs. 96% for the dexamethasone). It also induced potent inhibition in the rat carrageenan foot oedema test with an ID50 (0.14 μM kg-1) comparable with that of N-(2,6-diisopropylphenyl)phthalimide (4) (0.15 μM kg-1).

Synthesis and potent tumour necrosis factor-α production inhibitory activity of N-pyridinylphthalimides and derivatives

A series of N-azaaryl(alkyl)phthalimides incorporating amino(alkyl)pyridines were synthesized and tested as inhibitors of TNF-α production. The most potent compounds were N-(4,6-dimethyl-pyridin-2-yl)tetrafluorophthalimide (8, 40% inhibition at 10 μM), N-(3-methylpyridinyl)-5-fluorophthalimide (12, 48%) and N-(3-methylpyridinyl)tetrafluorophthalimide (13, 68%). The analogues without (tetra)fluorine substitution on the aromatic ring were less active inhibitors.

(N-phthalimidoalkyl) piperidines useful as treatments for psychosis

There is described novel (N-phthalimidoalkyl) piperidine compounds which exhibit selective sigma-receptor antagonism and therefore are useful in the treatment of physiological or drug induced psychosis and dyskinesia in a mammal. Also described are pharmaceutical compositions containing sigma selective compounds and methods of using these compositions for treating physiological or drug induced psychosis or dyskinesia in a mammal. Further provided are methods for preparing the compounds of this invention.